Indium-111 capromab pendetide in the management of recurrent prostate cancer

The provision of accurate prognostic information is a long-standing goal for effective management of prostate adenocarcinoma. Nontargeted imaging modalities are less efficient at detecting slow-growing prostate cancers. Prostate-specific membrane antigen has emerged as a superior biomarker, especially for the evaluation of metastatic spread. Advances in imaging technology have focused clinical interest on indium-111 capromab (111In capromab) pendetide, a radioimmunoconjugate that detects prostate-specific membrane antigen expression in vivo. Single-photon emission computed tomography capromab pendetide images, fused with those generated by computed tomography or magnetic resonance, have engendered improvements in localization accuracy by correlating high signal intensity with anatomic structures. In long-term outcomes studies, fused 111In capromab pendetide scans have delivered significant benefits for patient selection and improved treatment of prostate cancer.

[1]  T. Turkington,et al.  ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. , 2005, AJR. American journal of roentgenology.

[2]  G H Hinkle,et al.  Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. , 1999, Urology.

[3]  G H Hinkle,et al.  Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium‐111 capromab pendetide , 1998, Cancer.

[4]  I. Tannock,et al.  Management of advanced prostate cancer after first-line chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Oh.  The evolving role of estrogen therapy in prostate cancer. , 2002, Clinical prostate cancer.

[6]  Ralph Weissleder,et al.  Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. , 2003, The New England journal of medicine.

[7]  Y. Erdi,et al.  Tumor Localization of 16β-18F-Fluoro-5α-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer , 2004 .

[8]  W. Fair,et al.  Expression of the prostate-specific membrane antigen. , 1994, Cancer research.

[9]  Richard D. Williams,et al.  Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Abdelmonem A Afifi,et al.  Geographic and socioeconomic variation in the treatment of prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Breau,et al.  Spread of Prostate Carcinoma to the Perirectal Lymph Node Basin: Analysis of 112 Rectal Resections Over a 10-year Span for Primary Rectal Adenocarcinoma , 2004, American Journal of Surgical Pathology.

[12]  R. Lerski,et al.  Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Manyak,et al.  (111) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY , 1998 .

[14]  M. Manyak,et al.  111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. , 1998, The Journal of urology.

[15]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[16]  D. Mcleod,et al.  The emergence of radioimmunoscintigraphy for prostate cancer. , 2006, Reviews in urology.

[17]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.

[18]  S. Larson,et al.  Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer , 2005, Clinical Cancer Research.

[19]  S. Campbell,et al.  Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. , 2007, International journal of radiation oncology, biology, physics.

[20]  Pingfu Fu,et al.  Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. , 2007, Brachytherapy.

[21]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.

[22]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[23]  C. Pelizzari,et al.  Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  William C. Olson,et al.  The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Pingfu Fu,et al.  Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion. , 2007, Brachytherapy.

[26]  G. Bakale,et al.  Update on fused capromab pendetide imaging of prostate cancer. , 2005, Clinical prostate cancer.

[27]  Prabhjot Kaur,et al.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  A. Heidenreich,et al.  Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. , 2002, The Journal of urology.

[29]  A. Partin,et al.  Comparison of clinical staging algorithms and 111Indium‐capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients , 1999, Cancer.

[30]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[31]  Patrick W McLaughlin,et al.  Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Matthias D Hofer,et al.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.

[33]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[34]  B. Carey,et al.  Imaging for prostate cancer. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[35]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[36]  C. J. Schettino,et al.  Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. , 2004, AJR. American journal of roentgenology.

[37]  P. Unger,et al.  Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. , 1997, The Journal of urology.

[38]  F. Burkhard,et al.  Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? , 2003, The Journal of urology.

[39]  M. Manyak,et al.  Central abdominal uptake of indium-111 capromab pendetide (ProstaScint) predicts for poor prognosis in patients with prostate cancer. , 2007, Urology.

[40]  G. Chodak,et al.  The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. , 2004, The Journal of urology.

[41]  I. Thompson,et al.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.